Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 21, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, Inovio Pharmaceuticals, Inc. (INO) has a Wall Street consensus price target of $6.00, based on estimates from 17 covering analysts. With the stock currently trading at $1.81, this represents a potential upside of +231.5%. The company has a market capitalization of $65M.
Analyst price targets range from a low of $6.00 to a high of $6.00, representing a 0% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 9 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, INO trades at a trailing P/E of -0.5x. Analysts expect EPS to grow +32.9% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how INO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for INO is $6, representing 231.5% upside from the current price of $1.81. With 17 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
INO has a consensus rating of "Buy" based on 17 Wall Street analysts. The rating breakdown is predominantly bullish, with 9 Buy/Strong Buy ratings. The consensus 12-month price target of $6 implies 231.5% upside from current levels.
INO's current price is $1.81 with a consensus target of $6 (231.5% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $6 for INO, while the most conservative target is $6. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
INO is well covered by analysts, with 17 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 9 have Buy ratings, 6 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month INO stock forecast based on 17 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $6 (bear case) to $6 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on INO, with a "Buy" consensus rating and $6 price target (231.5% upside). 9 of 17 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
INO analyst price targets range from $6 to $6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.